Related Experiment Video

Updated: Apr 24, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.3K

Histone deacetylase inhibitors in oral squamous cell carcinoma treatment

Jason Tasoulas1, Constantinos Giaginis, Efstratios Patsouris

  • 1National and Kapodistrian University of Athens, Medical School, First Department of Pathology , Athens , Greece.

Expert Opinion on Investigational Drugs
|September 14, 2014
PubMed

Insights

Histone deacetylase inhibitors (HDACis) show promise as anticancer agents for oral squamous cell carcinoma (OSCC). Further research is needed to optimize their use as monotherapies or in combination treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Histone deacetylases (HDACs) play a crucial role in cancer development and progression.
  • HDAC inhibitors (HDACis) are a class of anticancer agents targeting HDACs.
  • HDACis have demonstrated significant antitumor activity in various human cancers, including OSCC.

Purpose of the Study:

  • To review current research on the anticancer activity of HDACis against OSCC.
  • To summarize the molecular mechanisms underlying HDACis action in OSCC.
  • To evaluate existing studies on the combined use of HDACis in OSCC therapy.

Main Methods:

  • Literature review of preclinical and clinical studies on HDACis in OSCC.
  • Analysis of molecular mechanisms of HDACis.
  • Synthesis of data on combination therapies involving HDACis for OSCC.

Main Results:

  • HDACis exhibit notable antitumor effects in OSCC models.
  • HDACis function through various molecular pathways impacting cancer cells.
  • Studies suggest potential benefits of combining HDACis with other therapeutic modalities for OSCC.

Conclusions:

  • HDACis represent promising therapeutic options for OSCC, potentially reducing side effects and allowing conservative treatment.
  • Further in vivo and clinical studies are essential to determine optimal dosage, treatment duration, and combination strategies for HDACis in OSCC.
  • Clinical implementation of HDACis for OSCC requires comprehensive evaluation of their efficacy and safety as monotherapies or in combination regimens.
Keywords:
anticancer therapyhistone deacetylase inhibitorshistone deacetylasesoral squamous cell carcinoma

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

7.5K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.3K